CECR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12177434	0.61	11/20
SCHEMBL15067688	0.55	9/20
SCHEMBL15647909	0.54	8/20
SCHEMBL2485668	0.42	8/20
SCHEMBL2112181	0.51	7/20
SCHEMBL7454709	0.34	6/20
SCHEMBL12177211	0.57	5/20
SCHEMBL12177556	0.55	5/20
SCHEMBL15957091	0.55	5/20
SCHEMBL15957174	0.53	5/20
SCHEMBL12177294	0.53	5/20
SCHEMBL10667729	0.47	5/20
SCHEMBL13005444	0.41	5/20
SCHEMBL13629854	0.39	5/20
SCHEMBL15957196	0.55	4/20
SCHEMBL15956937	0.53	4/20
SCHEMBL15956878	0.52	4/20
SCHEMBL15956889	0.51	4/20
SCHEMBL13329893	0.49	4/20
SCHEMBL15069208	0.48	4/20

Clinical trials — most relevant to CECR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
The PRE-OP ENERGY Trial	nan	UNKNOWN
Sperm Epigenome in Hodgkin Lymphoma	nan	NOT_YET_RECRUITING
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Precision High-Intensity Training Through Epigenetics (PHITE)	nan	COMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Age Related Chromatin Remodelling as a Therapeutic Target for Organ Protection in Cardiac Surgery	nan	ACTIVE_NOT_RECRUITING
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Genetic of SportS Induced Endofibrotic Remodeling	nan	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Analysis of DNA Methylation in Spondyloarthritis	nan	COMPLETED
Genetic Markers of Coronary Heart Disease in Type 2 Diabetes	nan	COMPLETED
Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Family Resilience Initiative Research Program	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CECR2 binder may also engage these)

Protein	Name	Similarity
E9Q2Z1	—	1.000	E9Q2Z1 →
MIDEAS	Mitotic deacetylase-associated SANT domain protein	0.997	landscape →
BAZ2A	Bromodomain adjacent to zinc finger domain protein 2A	0.994	landscape →
A2AHC3	—	0.994	A2AHC3 →
Q91YE5	—	0.994	Q91YE5 →
Q76N89	—	0.993	Q76N89 →
Q76LL6	—	0.993	Q76LL6 →
Q9Y2H5	—	0.993	Q9Y2H5 →
O18805	—	0.993	O18805 →
Q922B9	—	0.993	Q922B9 →
Q6PCQ0	—	0.992	Q6PCQ0 →
P48382	—	0.992	P48382 →
Q4G112	—	0.992	Q4G112 →
A7XYJ6	—	0.992	A7XYJ6 →
Q8BZ32	—	0.992	Q8BZ32 →
Q8VDP4	—	0.992	Q8VDP4 →
Q9JL04	—	0.992	Q9JL04 →
Q8R5I7	—	0.992	Q8R5I7 →
Q80YR5	—	0.992	Q80YR5 →
P28322	—	0.992	P28322 →
A0JPN4	—	0.991	A0JPN4 →
B2RRE7	—	0.991	B2RRE7 →
E1BE02	—	0.991	E1BE02 →
Q9BQK8	—	0.991	Q9BQK8 →
Q9Y6A5	—	0.991	Q9Y6A5 →
A7XYH5	—	0.991	A7XYH5 →
A6QLA6	—	0.991	A6QLA6 →
NFRKB	Nuclear factor related to kappa-B-binding protein	0.991	landscape →
O70405	—	0.991	O70405 →
Q76I79	—	0.991	Q76I79 →